The Thesis

Tesla at $343.25 is mispriced, and the neutral 43/100 signal score tells me the market is caught in a fog of short-term noise while ignoring the structural inflection points stacking up in Q2 and Q3 2026. Yes, the stock is down nearly 1% today. Yes, the "rough year continues" headlines are dominating the narrative. And yes, only 1 earnings beat out of the last 4 quarters looks ugly on a spreadsheet. But I have been in this seat long enough to know that the best Tesla entries come when the consensus crowd is busy writing eulogies.

Terafab Is the Story Nobody Is Pricing Correctly

Let me be blunt. The Terafab AI chip initiative is the single most underappreciated catalyst in mega-cap tech right now. The news flow this week confirms what I have been pounding the table on for months: Tesla is not just an automaker, not just an energy company, and not just a robotics play. It is building vertically integrated AI silicon at scale. Intel rocketing 11.4% on Terafab partnership hopes tells you everything you need to know about the magnitude of this opportunity. When your supply chain partners are adding billions in market cap on the mere association with your chip program, the market is telling you the TAM is enormous.

Pair that with easing autonomy regulatory pressure and you have a rare convergence. Tesla's custom AI chips feed directly into its FSD compute stack, its Optimus inference pipeline, and its Dojo training infrastructure. Regulatory tailwinds accelerate the monetization timeline for all three. This is not speculative. This is happening in real time.

The Signal Score Breakdown Reveals Opportunity

Let me walk through the components because they actually support a contrarian bullish case:

Analyst score: 49. Nearly half the Street is still modeling Tesla as a car company with shrinking margins. They are wrong, and they will revise upward when Terafab timelines crystallize and FSD regulatory approvals hit.

News score: 40. Dominated by "rough year" narratives and competitor noise like Candela's electric ferry order from Norway. Interesting tech, sure, but a 20-unit hydrofoil order is a rounding error compared to Tesla's delivery machine pushing north of 500K units per quarter globally.

Insider score: 14. This is the one number that gives me pause. Low insider buying suggests management is not aggressively accumulating at these levels. But context matters. Elon's compensation structure and existing ownership stake make traditional insider buying signals less relevant for Tesla than for virtually any other company in the S&P 500.

Earnings score: 58. The highest component, and the one the bears are ignoring. A 58 tells me the forward earnings trajectory is improving even if the trailing beat rate of 1 out of 4 looks weak. I expect Q2 2026 to be the inflection quarter where automotive margins stabilize above 18% and energy plus services revenue pushes total gross margins back toward 22%.

Execution Is the Only Thing That Matters Now

I do not care about the stock price yesterday or the headline from some generalist publication asking "time to buy?" in a question mark headline designed to generate clicks. What I care about is execution on three fronts:

1. Delivery volume. Tesla needs to push past 520K units in Q2 2026 to silence the demand destruction narrative. Early supply chain checks suggest this is achievable with Model Y refresh demand ramping in Europe and China.

2. FSD revenue recognition. Deferred revenue from FSD subscriptions is a $3B+ balance sheet asset waiting to flow through the income statement as regulatory approvals unlock supervised and unsupervised autonomy in new geographies.

3. Terafab timeline. First silicon samples expected in late 2026. If Tesla hits that milestone, the re-rating will be violent and fast.

The Competitive Moat Is Widening

While the market obsesses over quarterly delivery misses, Tesla is building inference compute, training compute, humanoid robotics, and grid-scale energy storage simultaneously. No other company on Earth is executing across all four vectors. The Terafab initiative alone could be worth $50 to $80 per share in a sum-of-the-parts framework once production economics become visible.

Bottom Line

TSLA at $343.25 with a 43/100 signal score is a gift for investors with a 12 to 18 month horizon. The Terafab catalyst, easing regulatory pressure on autonomy, and an improving earnings trajectory are converging into what I believe will be a powerful re-rating in the second half of 2026. I am not waiting for consensus to catch up. The best entries always feel uncomfortable, and this one has my full attention.